Trial Profile
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies, accompanying research(WJOG8916GTR)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms WJOG8916GTR
- 06 May 2022 Status changed from active, no longer recruiting to completed.
- 02 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 20 Jun 2017 Status changed from not yet recruiting to recruiting.